

Mark Hazebroek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3425739/publications.pdf>

Version: 2024-02-01

15
papers

550
citations

1040056

9
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

938
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the <sc>HOMAGE</sc> clinical trial. <i>European Journal of Heart Failure</i> , 2022, 24, 321-331.	7.1	16
2	Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the <sc>HOMAGE</sc> trial. <i>European Journal of Heart Failure</i> , 2022, 24, 771-778.	7.1	7
3	Global Longitudinal Strain is Incremental to Left Ventricular Ejection Fraction for the Prediction of Outcome in Optimally Treated Dilated Cardiomyopathy Patients. <i>Journal of the American Heart Association</i> , 2022, 11, e024505.	3.7	21
4	Dynamic Ejection Fraction Trajectory in Patients With Dilated Cardiomyopathy With a Truncating Titin Variant. <i>Circulation: Heart Failure</i> , 2022, 15, 101161CIRCHEARTFAILURE121009352.	3.9	9
5	Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences. <i>European Heart Journal</i> , 2021, 42, 162-174.	2.2	62
6	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	3.0	4
7	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. <i>JACC: Heart Failure</i> , 2021, 9, 268-277.	4.1	46
8	Identification of sex-specific biomarkers predicting new-onset heart failure. <i>ESC Heart Failure</i> , 2021, 8, 3512-3520.	3.1	11
9	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart OMics™ in AGEing (HOMAGE) randomized clinical trial. <i>European Heart Journal</i> , 2021, 42, 684-696.	2.2	77
10	Implications of Genetic Testing in Dilated Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, 476-487.	3.6	52
11	Distinct Cardiac Transcriptomic Clustering in Titin and Lamin A/C-Associated Dilated Cardiomyopathy Patients. <i>Circulation</i> , 2020, 142, 1230-1232.	1.6	7
12	Should we still monitor QTc duration in frail older patients on low-dose haloperidol? A prospective observational cohort study. <i>Age and Ageing</i> , 2020, 49, 829-836.	1.6	2
13	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005897.	3.9	63
14	Immunosuppressive Therapy Improves Both Short- and Long-Term Prognosis in Patients With Virus-Negative Nonfulminant Inflammatory Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2018, 11, e004228.	3.9	65
15	Relevance of cardiac parvovirus <sc>B19</sc> in myocarditis and dilated cardiomyopathy: review of the literature. <i>European Journal of Heart Failure</i> , 2016, 18, 1430-1441.	7.1	108